0001034842 false 0001034842 2023-01-09 2023-01-09 0001034842 dei:FormerAddressMember 2023-01-09 2023-01-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares






Washington, D.C. 20549





Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): January 9, 2023



(Exact name of registrant as specified in its charter)



(State or other jurisdiction of incorporation)


0-29889   94-3248524
(Commission File No.)   (IRS Employer Identification No.)
611 Gateway Boulevard    
Suite 900    
South San Francisco, CA   94080
(Address of principal executive offices)   (Zip Code)


Registrant’s telephone number, including area code: (650) 624-1100


1180 Veterans Boulevard

South San Francisco, CA 94080 

(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Title of Each Class   Trading
  Name of Each Exchange on Which
Common Stock, par value $0.001 per share   RIGL   The Nasdaq Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨







Item 2.02. Results of Operations and Financial Condition.


In connection with the press release described in Item 8.01 below, on January 9, 2023, Rigel Pharmaceuticals, Inc. (“Rigel”) provided, on a preliminary and unaudited basis, certain estimated financial results for its fourth quarter and fiscal year ended December 31, 2022. The preliminary estimates are based on currently available information and do not present all necessary information for a complete understanding of Rigel’s financial condition as of December 31, 2022 or Rigel’s results of operations for the fourth quarter or year ended December 31, 2022.


Item 8.01. Other Events.


On January 9, 2023, Rigel issued a press release titled “Rigel Pharmaceuticals Provides Business Update.” A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.


Item 9.01. Financial Statements and Exhibits.


(d) Exhibits.


Exhibit   Description
99.1   Press Release, dated January 9, 2023, titled “Rigel Pharmaceuticals Provides Business Update”
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: January 9, 2023 RIGEL PHARMACEUTICALS, INC.
    By: /s/ Ray Furey, J.D.
      Ray Furey, J.D.
      Executive Vice President, General Counsel and Corporate Secretary